Biocryst Pharmaceuticals (BCRX) Revenue Growth (3y) (2013 - 2026)
Biocryst Pharmaceuticals (BCRX) Revenue Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 2.84% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 4.19% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -4.46% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 15.52% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -2.00% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 24.66% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 2.94% |
| 10 | Biocryst Pharmaceuticals | 2.35 Bn | 2.28 Bn | 151.04 Mn | 31.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.50% |
| Dec 31, 2025 | -79.28% |
| Sep 30, 2025 | 28.10% |
| Jun 30, 2025 | 35.59% |
| Mar 31, 2025 | 42.85% |
| Dec 31, 2024 | 40.76% |
| Sep 30, 2024 | 41.88% |
| Jun 30, 2024 | 29.83% |
| Mar 31, 2024 | 69.47% |
| Dec 31, 2023 | 185.44% |
| Sep 30, 2023 | 142.24% |
| Jun 30, 2023 | 206.28% |
| Mar 31, 2023 | 142.50% |
| Dec 31, 2022 | 26.04% |
| Sep 30, 2022 | 249.58% |
| Jun 30, 2022 | 256.36% |
| Mar 31, 2022 | 103.92% |
| Dec 31, 2021 | 158.53% |
| Sep 30, 2021 | 204.36% |
| Jun 30, 2021 | 58.72% |